Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

OKYO vs CCCC: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

OKYO Captures Overall Composite Edge (42.8 HOLD vs 57.7 HOLD), While CCCC Leads 3–2 on Growth & Valuation Pillars

OKYO Overall Winner 6-Pillar Tally: OKYO 2 – 3 CCCC (1 Tie) Matrix Metrics: OKYO 3 – 5 CCCC

As of Nov 20, 2026, OKYO Pharma Limited (OKYO) captures the overall head-to-head institutional edge over C4 Therapeutics, Inc. (CCCC) on higher Unified Composite conviction (42.8/100 HOLD vs. 57.7/100 HOLD) after splitting the core matrix 3–5 (led by Profitability & Quality, Options & Positioning), while CCCC wins 3–2 across the 6-pillar growth and valuation breakdown. OKYO trades at $1.07 (N/M Forward P/E, 0.0% operating margin) versus CCCC at $2.48 (N/M Forward P/E, -315.9% operating margin).

  • Composite vs. Pillar Nuance: While CCCC currently prints a higher short-term Unified Composite Score (57.7/100 HOLD vs. OKYO 42.8/100 HOLD), OKYO captures the overall institutional head-to-head verdict (3–5 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -315.9% operating margin) and revenue trajectory (+0.0% vs. -24.6% YoY).
  • Technical & Structure Timing Caution: OKYO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.8); meanwhile CCCC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About OKYO vs CCCC
OKYO NASDAQ Head-to-Head Winner
OKYO Pharma Limited Ordinary Shares
Biological Products, (No Diagnostic Substances)
$1.07
-7.76% 1D
Market Cap $62.7M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.05β · 76% Vol
Unified Composite Score
42.8 / 100 HOLD
Tech 38.0 Fund 54.0 Flow 50.0 Mom 45.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.9%), weak momentum, RSI 32
RSI-14: 31.8 · SMA20: $1.35 · SMA50: $1.38
CCCC NASDAQ
C4 Therapeutics, Inc.
Biological Products, (No Disgnostic Substances)
$2.48
+1.64% 1D
Market Cap $325.7M
TTM Revenue $32M
Forward P/E N/M
Beta / 30D Vol 1.25β · 60% Vol
Unified Composite Score
57.7 / 100 HOLD
Tech 58.0 Fund 60.0 Flow 64.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -11.2%), weak momentum, RSI 33
RSI-14: 33.3 · SMA20: $2.95 · SMA50: $3.03

6-Pillar Scorecard Institutional Category Breakdown (OKYO 2 – 3 CCCC)

Columns: Metric · OKYO · CCCC
1. Valuation Multiples CCCC
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 10.8x
2. Growth & Scale CCCC
Revenue Growth (YoY) +0.0% -24.6%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $32M
Market Cap $62.7M $325.7M
3. Profitability & Quality OKYO
Gross Margin N/A 88.8%
Operating Margin 0.0% -315.9%
Net Profit Margin 0.0% -282.2%
Return on Equity (ROE) -263.8% -47.6%
4. Balance Sheet & Cash Flow CCCC
Cash Generation (TTM) N/A -$80M
Cash Flow Margin N/A N/A
Net Cash / Leverage $0.23 Book/Sh · -263.8% ROE $23M Net Debt (0.24x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning OKYO
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 79.8% (3rd %ile)
Put/Call OI Skew N/A 0.44x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: OKYO (3) vs CCCC (5)
Institutional Metric OKYO CCCC Criterion Row Edge
Market Capitalization
Scale
$62.7M $325.7M Larger Scale CCCC
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% -24.6% Higher Growth OKYO
Operating Margin (TTM)
Profitability
0.0% -315.9% Higher Margin OKYO
Net Profit Margin
Profitability
0.0% -282.2% Higher Margin OKYO
Return on Equity (ROE)
Capital Efficiency
-263.8% -47.6% Higher ROE CCCC
52-Week Range Position
Momentum
3% ($1–$3) 23% ($2–$5) Stronger Trend CCCC
Beta / 30D Volatility
Risk Regime
1.05β · 76% Vol 1.25β · 60% Vol Lower Realized Risk CCCC
Unified Institutional Score
Composite Signal
42.8 / 100 (HOLD) 57.7 / 100 (HOLD) Higher Composite CCCC
Trailing 12M Revenue (USD)
Operating Scale
N/A $32M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 88.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 10.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($0.23 Book/Sh · -263.8% ROE) -$80M ($23M Net Debt (0.24x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CCCC +5.2 pp
OKYO: -27.21% · CCCC: -22.01%
3M Horizon OKYO +10.84 pp
OKYO: -28.67% · CCCC: -39.51%
6M Horizon CCCC +4.02 pp
OKYO: -34.36% · CCCC: -30.34%
1Y Horizon CCCC +46.23 pp
OKYO: -47.03% · CCCC: -0.8%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on OKYO vs CCCC. Trailing 12-month operating profitability (OKYO 0.0% vs CCCC -315.9%) and valuation multiples (OKYO N/M vs CCCC N/M Forward P/E) are benchmarked directly in Pillar 4 below.

OKYO ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-263.8% · N/M
CCCC ADR TTM Benchmark FX-Normalized USD
TTM Revenue$32M
Gross Margin88.8%
Op. Margin-315.9%
ROE / Fwd P/E-47.6% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
OKYO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact OKYO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CCCC BREAKDOWN
121d in phase · OBV DISTRIBUTION
Current IV 79.8%
IV Percentile 3rd %ile
Put/Call OI Skew 0.44x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact CCCC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
OKYO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $62.7M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CCCC Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $325.7M market capitalization and -315.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ OKYO vs CCCC Key Questions & Quantitative Answers

As of Nov 20, 2026, OKYO Pharma Limited (OKYO) captures the overall head-to-head institutional edge over C4 Therapeutics, Inc. (CCCC) on higher Unified Composite conviction (42.8/100 HOLD vs. 57.7/100 HOLD) after splitting the core matrix 3–5 (led by Profitability & Quality, Options & Positioning), while CCCC wins 3–2 across the 6-pillar growth and valuation breakdown. OKYO trades at $1.07 (N/M Forward P/E, 0.0% operating margin) versus CCCC at $2.48 (N/M Forward P/E, -315.9% operating margin). Composite vs. Pillar Nuance: While CCCC currently prints a higher short-term Unified Composite Score (57.7/100 HOLD vs. OKYO 42.8/100 HOLD), OKYO captures the overall institutional head-to-head verdict (3–5 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -315.9% operating margin) and revenue trajectory (+0.0% vs. -24.6% YoY). Technical & Structure Timing Caution: OKYO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.8); meanwhile CCCC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CCCC leads the Growth & Scale pillar: OKYO posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with CCCC at -24.6% YoY revenue growth and +0.0% YoY earnings growth on $32M TTM revenue (88.8% gross margin, -315.9% operating margin). On trailing 12-month operating scale, OKYO generates N/A in USD-normalized revenue versus $32M for CCCC. In operating R&D and SG&A reinvestment, OKYO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CCCC.

CCCC screens cheaper on headline valuation multiples. OKYO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas CCCC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 10.8x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against OKYO (-263.8% ROE) versus CCCC (-47.6% ROE) capital efficiency.

In options market volatility and institutional positioning, OKYO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.05β · 76% Vol realized risk). By comparison, CCCC carries 79.8% implied volatility (3rd %ile, Compressed (<25th %ile)), a 0.44x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.25β · 60% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.